Compare Medpace Holdings Inc (MEDP) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Schlumberger NV — how do they compare? Medpace Holdings Inc trades at $530 (market cap $15.08B), while Schlumberger NV trades at $46.77 (market cap $69.36B). The key difference: Schlumberger NV is far larger — about 4.6× Medpace Holdings Inc's market cap, and Schlumberger NV pays a 2.54% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | SLB | |
|---|---|---|
Market Cap | $15.08B | $69.36B |
Sector | Technology | Energy |
52-Week High | $620.59 | $58.01 |
52-Week Low | $308.88 | $31.72 |
Enterprise Value | $14.55B | $77.58B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
SLB trades at $46.59, down 0.85% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with a 9.26% net margin and 14.57% ROE, supported by $6.5B in operating cash flow. Recent strategic moves include a partnership with Liberty Energy for data center power solutions and major contract wins like the Baleine Phase 3 EPC award, positioning SLB to capitalize on energy and AI infrastructure demand.
The outlook is cautiously optimistic with an 84.85% analyst buy rating and a $62.83 consensus price target implying 35% upside. Risks include oil price volatility and execution challenges in new ventures, but SLB's solid balance sheet and digital growth initiatives offer a compelling case for long-term investors amid near-term market weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
